



Wezlana in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

IMMUNOLOGY · STELARA BIOSIMILAR (IL-12/23)

The clinical situation

Wezlana (ustekinumab-auub) is an FDA-approved interchangeable biosimilar to Stelara, an anti-IL-12/23 p40 monoclonal antibody for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Manufactured by Amgen. Dosing mirrors the reference product: SC or IV per indication with weight-based loading and quarterly maintenance. Pre-treatment workup covers TB screening, hepatitis B/C, and vaccination status per FDA labelling, with the same class safety profile as ustekinumab.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your specialist documents indication, severity, prior biologics, and Wezlana rationale including biosimilar-interchangeability justification.
- 2 Baseline screening.** TB, hepatitis B/C, vaccinations, and infection review completed per FDA labelling.
- 3 MoHAP named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, dosing calendar, and chain-of-custody plan; DHA or DoH approvals align where applicable.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with validated 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases product against the prescription; your physician initiates therapy with ongoing IL-12/23-class monitoring.

Indicative economics

Reference US cash-pay range: USD 18,000–22,000 per Wezlana maintenance dose (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete MoHAP application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Amgen authorised distribution.

Documentation. Physician kit tailored to MoHAP / DHA / DoH review, with biosimilar-interchangeability annex. **Logistics.**

Validated cold-chain internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through the case arc. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Wezlana × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/wezlana-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team